Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 29 of 40 · 1919 articles
PROM completion is important for monitoring symptoms and disease control between visits. The study shows a single empowerment campaign produced a short‑term boost in PROM response but not sustained engagement,...
Researchers found distinct microbial and host molecular features in the appendices of children with IBD, which could help explain local immune activation and guide future studies of disease mechanisms or biomarkers.
A market analysis listing late‑stage investigational therapies and growing use of IL‑23 and S1P pathway drugs signals potential new treatment options and changing prescribing patterns that may affect access, choice, and...
Dietary strategies are commonly considered by people with IBD to manage symptoms and quality of life. This trial focuses on real-world adherence and patient-reported barriers to three popular diets (intermittent fasting,...
New analytical tools for longitudinal microbiome data can reveal time-varying microbial signatures tied to Crohn's disease and ulcerative colitis. Identifying such biomarkers may eventually inform diagnosis, monitoring,...
Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Hydrocortisone injection is an FDA‑labelled corticosteroid option for short‑term control of severe flares or life‑threatening situations when oral therapy isn't feasible; the label explicitly names regional enteritis...
The study identifies a compound (DDIE) that reduced cellular senescence and improved colitis in a mouse model by modulating AKT and GSK3B, suggesting a new avenue for drug development in ulcerative colitis focused on...
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...
The study identifies a plant extract that reduced inflammation and oxidative stress and altered molecular pathways (Nrf2/Keap1, NF-κB) and lncRNA expression in a rat colitis model—potential leads for future IBD research...
The work suggests a microbe–metabolite–immune pathway (B. pseudolongum → taurine metabolites → M2 macrophages) that could point to future microbiome- or metabolite-targeted therapies for ulcerative colitis, which may be...
IBD may involve small-vessel changes beyond the gut. If reproducible, retinal microvascular alterations detectable by OCTA could offer a non-invasive window into systemic microvascular involvement in IBD.
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
This study describes a new formulation of baicalein that improved drug solubility and oral absorption and showed benefit in a mouse model of ulcerative colitis—early-stage research that could inform future...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
This report links a rare kidney disease (FGN) with ulcerative colitis in a young adult and raises atypical familial Mediterranean fever as a possible underlying autoinflammatory cause; recognizing this could change...
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
A nationwide clinician survey identifies major variation in how acute severe ulcerative colitis is diagnosed, monitored, and when rescue therapy or surgery is used — differences that can affect patient outcomes and...
Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...
If you have IBD and are taking or considering a GLP‑1 drug for obesity or diabetes, this large claims-based study did not find that those drugs lowered the risk of IBD relapse — so they shouldn’t be expected to improve...
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
If local complement Factor B helps the gut heal, it could change how researchers think about targeting complement in IBD — suggesting local regulation rather than systemic inhibition. That’s important because complement...
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to...
Caldera’s funding and Nasdaq listing mean the company can run phase 2 trials in ulcerative colitis and Crohn’s disease of a bispecific drug that targets two immune pathways. If successful, that approach could change...
A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...
The trial tests a palatable elemental diet (mBIOTA) as a non-drug approach for treating outpatient IBD flares, which could reduce reliance on steroids and other medications if shown effective and tolerable.
The paper suggests that HRQoL and family functioning may be similar across disease types and common treatment approaches in children with IBD, but emotional health and parental worry remain areas needing attention.
Cure8 could only read part of this source from newsbytesapp.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...
If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.
The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.
This study suggests that boosting Nrf2 activity in CD4+ T cells can reduce inflammatory Th1/Th17 responses and increase regulatory T cells, which may help control colonic inflammation in ulcerative colitis.
The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory...
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
The study suggests C. difficile colonization may expand IL1B+ monocytes that recruit neutrophils and amplify inflammation in ulcerative colitis, a pathway that could help explain pathogen-associated flares.
This large US claims study compares safety outcomes (serious infections, heart attacks/stroke, and venous clots) for tofacitinib versus multiple biologic therapies in people with ulcerative colitis — questions many...
The work suggests soluble factors present in fecal filtrates from active UC patients can provoke proinflammatory responses in a controlled intestine-on-chip model, supporting the idea that microbiome-derived metabolites...
An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...
